Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

類似資料

• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
  著者:: Kahn, SE, 等
  出版事項: (2006)
• Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
  著者:: Kahn, SE, 等
  出版事項: (2011)
• Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
  著者:: Zinman, B, 等
  出版事項: (2010)
• Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain
  著者:: Haffner, S, 等
  出版事項: (2007)
• ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes
  著者:: Herman, W, 等
  出版事項: (2007)